Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
lobsor.com

See what CB Insights has to offer

Founded Year

2013

Stage

Acquired | Acquired

About Lobsor Pharmaceuticals

Lobsor Pharmaceuticals is a development project working on treating Parkinson's disease in advanced stages.On October 2nd, 2020, Lobsor Pharmaceuticals was acquired by Stada Arzneimittel. Terms of the transaction were not disclosed.

Lobsor Pharmaceuticals Headquarter Location

Kalsangsgrand 10 D

Uppsala, 753 19,

Sweden

Latest Lobsor Pharmaceuticals News

Parent company of Thronton & Ross acquires Parkinson’s disease therapy

Oct 5, 2020

The parent company of Huddersfield-based Thornton & Ross (T&R) has strengthened its footprint in specialty pharmaceuticals by acquiring a therapy used for treating late-stage Parkinson’s disease. Updated Peter Goldschmidt, CEO of STADA: “This acquisition of Lobsor significantly expands STADA’s specialty footprint". STADA has snapped up Lobsor Pharmaceuticals, has gained the rights to a triple fixed combination, levodopa, carbidopa and entacapone, delivered through modern pump technology, Peter Goldschmidt, CEO of STADA, said: “This acquisition of Lobsor significantly expands STADA’s specialty footprint and serves as further evidence that STADA is a leading go-to-partner for specialty pharmaceuticals, generics and consumer health products. Sign up to our daily newsletter The i newsletter cut through the noise Sign up Submitting... “It also complements our portfolio and expertise in the treatment of late-stage Parkinson’s disease, where we have strong expertise via our company Britannia Pharmaceuticals headquartered in Reading.” STADA is the parent company of Thornton & Ross, which employs more than 500 people at its headquarters in Huddersfield. The firm offers a wide and diverse portfolio of generic pharmaceuticals and over the counter healthcare solutions. --- Support The Yorkshire Post and become a subscriber today. Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers. So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust. Thank you

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lobsor Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lobsor Pharmaceuticals is included in 1 Expert Collection, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Lobsor Pharmaceuticals Patents

Lobsor Pharmaceuticals has filed 5 patents.

The 3 most popular patent topics include:

  • Monoamine oxidase inhibitors
  • Abandoned drugs
  • Hepatotoxins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/3/2018

9/29/2020

Monoamine oxidase inhibitors, Hepatotoxins, Abandoned drugs, Antidepressants, Amines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/3/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/29/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoamine oxidase inhibitors, Hepatotoxins, Abandoned drugs, Antidepressants, Amines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.